SUBSCRIBE
SUBSCRIBE

Anti-Delirium Drug May Harm Critically Ill Patients, University Medical Center Utrecht Study

November 5, 2010 | 
1 min read

THURSDAY, Nov. 4 (HealthDay News) -- The anti-delirium drug rivastigmine (brand name Exelon) does not appear to control delirium in critically ill hospital patients, new Dutch research indicates.

Europe
MORE ON THIS TOPIC
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Weigh scales on pink background, top view with space for text. Overweight concept
Obesity
UK Pharmacies Regulator Wants Tighter Checks on Weight Loss Injections
February 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
Trump’s Tariffs Threaten Big Pharma With Higher Costs and Slimmer Margins
February 3, 2025
 · 
3 min read
 · 
Tristan Manalac
Biogen’s headquarters in Massachusetts
Layoffs
Biogen Trims Research Workforce, Higher-Dose SMA Drug Accepted for Regulatory Review
January 23, 2025
 · 
3 min read
 · 
Tristan Manalac